18.11.2026 14:30:05 - dpa-AFX: GNW-News: Evaxion to announce strategy and business update and third quarter 2026 financial results on November 19, 2026
COPENHAGEN, Denmark, November 18, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"),
a clinical-stage TechBio company developing novel immunotherapies with its
pioneering AI-Immunology(TM) platform, will provide a strategy and business update
and report its third quarter 2026 financial results on Thursday November
19, 2026, before opening of the Nasdaq CM.
Evaxion's executive management will host a conference call and webcast at
8.30am ET/14.30 CET the same day, presenting the strategy and business update
and financial results as well as taking questions.
To join the conference call, listen to the presentation and ask verbal
questions, please register in advance via this link (https://register-
conf.media-server.com/register/BI3c826c95e7e84fbaa23ff771ad3297e9) to receive
the dial-in telephone numbers and a unique PIN code. The call can be accessed
15 minutes prior to the start of the live event.
To join the webcast, please click on this link (https://edge.media-
server.com/mmc/p/boph6dc4). The webcast recording will be available on our
website shortly after the event.
Contact information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai (mailto:mak@evaxion.ai)
About Evaxion
Evaxion is a pioneering clinical-stage TechBio company based upon its
proprietary, clinically validated and scalable AI platform, AI-Immunology(TM). The
platform harnesses the power of artificial intelligence to decode the human
immune system and develop novel immunotherapies for cancer as well as infectious
and autoimmune diseases.
With AI-Immunology(TM) we conduct rapid, efficient and high-quality target
discovery, drug design and development. Our team of +40 experts covers the
entire value chain from target discovery to clinical development.
We have developed a pipeline of both personalized and off-the-shelf cancer
vaccine candidates as well as prophylactic vaccine candidates for infectious
diseases. All our candidates address high unmet medical needs, reflecting our
commitment to transforming patients' lives by providing innovative and targeted
treatment options.
For more information about Evaxion, AI-Immunology(TM) and our pipeline, please
visit our website (https://evaxion.ai).
Forward-looking statement
This announcement contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. The words "target," "believe,"
"expect," "hope," "aim," "intend," "may," "might," "anticipate," "contemplate,"
"continue," "estimate," "plan," "potential," "predict," "project," "will," "can
have," "likely," "should," "would," "could," and other words and terms of
similar meaning identify forward-looking statements. Actual results may differ
materially from those indicated by such forward-looking statements as a result
of various factors, including, but not limited to, risks related to: our
financial condition and need for additional capital; our development work; cost
and success of our product development activities and preclinical and clinical
trials; commercializing any approved pharmaceutical product developed using our
AI platform technology, including the rate and degree of market acceptance of
our product candidates; our dependence on third parties including for conduct of
clinical testing and product manufacture; our inability to enter into
partnerships; government regulation; protection of our intellectual property
rights; employee matters and managing growth; our ADSs and ordinary shares, the
impact of international economic, political, legal, compliance, social and
business factors, including inflation, and the effects on our business from
other significant geopolitical and macro-economic events; and other
uncertainties affecting our business operations and financial condition. For a
further discussion of these risks, please refer to the risk factors included in
our most recent Annual Report on Form 20-F and other filings with the US
Securities and Exchange Commission (SEC), which are available at www.sec.gov
(https://www.globenewswire.com/Tracker?data=3eX-
yULjXHj_fAO4jPRASPaehYEVHM4NmXNAs_0lw5UK0DHjLXk6aKS6LI4PyMob9UvuFpZpGQrWa4b_6WQY
1A==). We do not assume any obligation to update any forward-looking statements
except as required by law.
Â